Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-22T17:42:00.724Z Has data issue: false hasContentIssue false
  • English
  • Français

Exploring the ameliorative potential of probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum on dextran sodium sulphate induced colitis in mice

Published online by Cambridge University Press:  14 January 2013

Sagar R. Jadhav ,
Umesh Kr. Shandilya  and
Vinod K. Kansal
Sagar R. Jadhav*
Affiliation:
Animal Biochemistry Division, National Dairy Research Institute, Karnal-132001, Haryana, India
Umesh Kr. Shandilya
Affiliation:
Animal Biochemistry Division, National Dairy Research Institute, Karnal-132001, Haryana, India
Vinod K. Kansal
Affiliation:
Animal Biochemistry Division, National Dairy Research Institute, Karnal-132001, Haryana, India
*
*For correspondence; e-mail: drsagarndri@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Conventional medical therapies for ulcerative colitis (UC) are still limited due to the adverse side effects like dose-dependent diarrhoea and insufficient potency to keep in remission for long-term periods. So, new alternatives that provide more effective and safe therapies for ulcerative colitis are constantly being sought. In the present study, probiotic LaBb Dahi was selected for investigation of its therapeutic effect on DSS-induced colitis model in mice. LaBb Dahi was prepared by co-culturing Dahi culture of Lactococci along with selected strain of Lactobacillus acidophilus LaVK2 and Bifidobacterium bifidum BbVK3 in buffalo milk. Four groups of mice (12 each) were fed for 17 d with buffalo milk (normal control), buffalo milk plus DSS (Colitis control), Dahi plus DSS, and LaBb Dahi plus DSS, respectively, with basal diet. The disease activity scores, weight loss, organ weight, colon length, myeloperoxidase (MPO) and β-glucoronidase activity was assessed, and the histopathological picture of the colon of mice was studied. All colitis control mice evidenced significant increase in MPO, β-glucoronidase activity and showed high disease activity scores along with histological damage to colonic tissue. Feeding with LaBb Dahi offered significant reduction in MPO activity, β-glucoronidase activity and improved disease activity scores. We found significant decline in length of colon, organ weight and body weight in colitis induced controls which were improved significantly by feeding LaBb Dahi. The present study suggests that LaBb Dahi can be used as a potential nutraceutical intervention to combat UC related changes and may offer effective adjunctive treatment for management of UC.

Keywords

Lactobacillus acidophilusBifidobacterium bifidumLaBb Dahiulcerative colitisdextran sodium sulphatemyeloperoxidase
Type
Research Article
Information
Journal of Dairy Research , Volume 80 , Issue 1 , February 2013 , pp. 21 - 27
Copyright
Copyright © Proprietors of Journal of Dairy Research 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

AOAC 2005 In Official Methods of Analysis, 18th edition, vol 45. pp. 75–76 (Ed. Horowitz, W). Gaithersburg: Association of Official Analytical ChemistsGoogle Scholar
Bibiloni, R, Fedorak, RN, Tannock, GW, Madsen, KL, Gionchetti, P, Campieri, M, De Simone, C & Sartor, RB 2005 VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. American Journal of Gastroenterology 100 1539–1546CrossRefGoogle ScholarPubMed
Bradley, PP, Priebat, DA, Christensen, RD & Rothstein, G 1982 Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. Journal of Investigative Dermatology 78 206–209Google Scholar
Campieri, M & Gionchetti, P 1999 Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative. Gastroenterology 116 1246–1260Google Scholar
Chapman, TM, Plosker, GL & Figgitt, DP 2007 Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases. BioDrugs 21 61–63CrossRefGoogle ScholarPubMed
Collins, MP & Gibson, GR 1999 Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. American Journal of Clinical Nutrition 69 s1052–1057Google Scholar
Cummings, JH, Macfarlane, GT & Macfarlane, S 2003 Intestinal bacteria and ulcerative colitis. Current Issues in Intestinal Microbiology 4 9–20Google ScholarPubMed
Fedorak, RN & Madsen, KL 2004 Probiotics and the management of inflammatory bowel disease. Inflammatory Bowel Disease 10 286–299Google Scholar
Food and Agriculture Organization of the United Nations (FAO) 2002 Guidelines for the evaluation of probiotics in food. London, Ontario, Canada: Joint FAO/WHO Working Group Report (http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf)Google Scholar
Fuller, R 1989 Probiotics in man and animals. Journal of Applied Bacteriology 66 365–378Google ScholarPubMed
Gillen, CD, Walmsley, RS, Prior, P, Andrews, HA & Allan, RN 1994 Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35 1590–1592Google Scholar
Hamamoto, N, Maemura, K, Hirata, I, Murano, M, Sasaki, S & Katsu, K 1999 Inhibition of dextran sulphate sodium (DSS) induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1). Clinical and Experimental Immunology 117 462–468Google Scholar
Hegazy, SK & El-Bedewy, MM 2010 Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World Journal of Gastroenterology 16 4145–4151Google Scholar
Herias, MV, Koninkx, JF, Vos, JG, Huis in't Veld, JH & van Dijk, JE 2005 Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. International Journal of Food Microbiology 103 143–55Google Scholar
Jakobovits, SL, Jewell, DP & Travis, SP 2007 Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Alimentary Pharmacology and Therapeutics 25 1055–1060CrossRefGoogle ScholarPubMed
Kamada, N, Maeda, K, Inoue, N, Hisamatsu, T, Okamoto, S, Hong, KS, Yamada, T, Watanabe, N, Suchimoto, K, Ogata, H & Hibi, T 2008 Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. Infection and Immunology 76 214–220CrossRefGoogle ScholarPubMed
Kaushal, D & Kansal, VK 2011 Probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum alleviates age-inflicted oxidative stress and improves expression of biomarkers of ageing in mice. Molecular Biology Reports 39 1791–1799Google Scholar
Kokesova, A, Frolova, L, Kverka, M, Sokol, D, Rossmann, P, Bartova, J & Tlaskalova-Hogenova, H 2006 Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. Folia Microbiologica (Praha) 51 478–484Google Scholar
Kruis, W 2004 Antibiotics and probiotics in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 20(Suppl. 4) 75–78Google Scholar
Langholz, E, Munkholm, P, Davidsen, M & Binder, V 1992 Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 103 1444–1451Google Scholar
Lee, JH, Lee, B, Lee, HS, Bae, EA, Lee, H, Ahn, YT, Lim, KS, Huh, CS & Kim, DH 2009 Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental colitis. International Journal of Colorectal Disease 24 2231–237Google Scholar
Lewis, JD, Gelfand, JM, Troxel, AB, Forde, KA, Newcomb, C, Kim, H, Margolis, DJ & Strom, BL 2008 Immunosuppressant medications and mortality in inflammatory bowel disease. American Journal of Gastroenterology 103 1428–1435CrossRefGoogle ScholarPubMed
Lowry, OH, Rosebrough, NJ, Farr, AL & Randall, RJ 1951 Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193 265–275Google Scholar
Madsen, KL, Doyle, JS, Jewell, LD, Tavernini, MM & Fedorak, RN 1999 Lactobacillus species prevents colitis in interleukin 10 gene deficient mice. Gastroenterology 116 1107–1114Google Scholar
Rajpal, S & Kansal, VK 2008 Buffalo milk probiotic Dahi containing Lactobacillus acidophilus, Bifidobacterium bifidum and Lactococcus lactis reduces gastrointestinal cancer induced by dimethylhydrazine dihydrochloride in rats. Milchwissenschaft 63 122–125Google Scholar
Rajpal, S & Kansal, VK 2009a Probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum attenuated diet induced hypercholesteromia in rats. Milchwissenschaft 64 21–25Google Scholar
Rajpal, S & Kansal, VK 2009b Probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum stimulates immune system in mice. Milchwissenschaft 64 147–150Google Scholar
Regueiro, M, Curtis, J & Plevy, S 2006 Infliximab for hospitalized patients with severe ulcerative colitis. Journal of Clinical Gastroenterology 40 476–481Google Scholar
Rioux, KP & Fedorak, RN 2006 Probiotics in the treatment of inflammatory bowel disease. Journal of Clinical Gastroenterology 40 260–263Google Scholar
Rosai, J 2004 Gastrointestinal tract, large bowel. In Rosai and Ackerman's Surgical Pathology, 9th edition. pp. 776–855. (Ed. Rosai, J). Philadelphia: MosbyGoogle Scholar
Sartor, RB 2004 Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics and prebiotics. Gastroenterology 126 1620–1633CrossRefGoogle ScholarPubMed
Sartor, RB 2008 Microbial influences in inflammatory bowel diseases. Gastroenterology 134 577–594Google Scholar
Shibolet, O, Karmeli, F, Eliakim, R, Swennen, E, Brigidi, P, Gionchetti, P, Campieri, M, Morgenstern, S & Rachmilewitz, D 2002 Variable response to probiotics in two models of experimental colitis in rats. Inflammatory Bowel Disease 8 399–406Google Scholar